Cnbx Pharmaceuticals INC 10-Q quarterly reports

CNBX Pharmaceuticals reports a net loss of $154,165 for the third quarter of 2026 as it continues to develop its oncology drug candidate, RCC-33.

CNBX Pharmaceuticals Inc. reported a wider net loss for the six months ended February 28, 2026, with cash reserves decreasing, raising going concern doubts.

CNBX Pharmaceuticals Inc. reported a significant increase in net loss and a critically low cash position for the three months ended November 30, 2025, raising substantial doubt about its ability to continue as a going concern.

CNBX Pharmaceuticals Inc. reported no revenue and a critically low cash position in its latest 10-Q filing, raising substantial doubt about its ability to continue as a going concern amidst a significant reduction in operational activities.

CNBX Pharmaceuticals' Q2 2025 report reveals decreased operating expenses due to funding constraints, alongside ongoing efforts to advance its colorectal cancer drug candidate.

CNBX Pharmaceuticals reported a net loss of $34,352 for the quarter ended November 30, 2024, with reduced operating expenses and ongoing concerns about its ability to continue as a going concern.

CNBX Pharmaceuticals' Q3 2024 results show a decrease in revenue but a reduced net loss compared to the same period last year, driven by lower operating expenses.

CNBX Pharmaceuticals reports increased revenue for Q2 2024 but faces ongoing concerns about its ability to continue as a going concern due to accumulated losses and limited cash resources.

CNBX Pharmaceuticals reports a decreased net loss for the three months ended November 30, 2023, while continuing to advance its cannabinoid-based cancer treatment programs.